ObsEva S.A.
NASDAQ: OBSV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William Michael Brown
- Employees
- 48
- Headquarters
- Geneva, Switzerland
- IPO year
- 2018
- Market cap
- $11.0M
- Website
- https://www.obseva.com
Loading OBSV…
Loading profile data…Frequently asked questions about OBSV
What does ObsEva S.A. (OBSV) do?
ObsEva S.A. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for conditions affecting women's reproductive health and pregnancy. A key part of their development pipeline is Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, currently in Phase III clinical tria...
Where does OBSV trade?
ObsEva S.A. (OBSV) trades on the NASDAQ Global Select.
What sector is OBSV in?
ObsEva S.A. (OBSV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ObsEva S.A.?
William Michael Brown is the chief executive officer of ObsEva S.A. (OBSV).
Where is ObsEva S.A. headquartered?
ObsEva S.A. is headquartered in Switzerland.
Does OBSV pay a dividend?
ObsEva S.A. (OBSV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OBSV go public?
ObsEva S.A. (OBSV) completed its initial public offering in 2018.